Interprofessional Approaches: Managing AEs of Novel Therapies for NHL/CLL.

Slides:

Advertisements

Similar presentations

The Patient Experience With Systemic Lupus Erythematosus

Advertisements

Moderate-to-Severe Asthma Management

Innovations and Issues in Mantle Cell Lymphoma

Relapsed/Refractory Follicular Lymphoma Conundrums

Tailoring Statin Therapy in Women

Updates in Hodgkin Lymphoma

Moderate-Intensity Statins for Dyslipidemia: How to Treat Today?

Renal and Extrarenal Complications of ADPKD: Facilitating Better Patient Care.

Continuing the Advances in Relapsed/Refractory CLL: New Data, New Paradigms.

Introduction. Risk Communication With Patients: Your Guide to Resources and Recommendations.

Current and Future Goals in the Treatment of Relapsed CLL

Goals of Therapy in Relapsed CLL

BTK Inhibitors in Relapsed/Refractory Mantle Cell Lymphoma

An Interprofessional Approach to the Patient With Chronic Airway Disease.

Clinical Considerations in Evidence-based Management of GIST

Updates in Follicular Lymphoma

Novel and Emerging Approaches to Treating CLL

The Nurse View.

When Would You Use Single Inhaler Triple Therapy in COPD?

Activity Goals. Activity Goals Case Presentation.

Talking to Patients About Diabetes Management

Case Study. Managing Medication and Adherence in SIHD: Partnering With the Patient to Improve Care.

Treatment Decisions in Chemorefractory Follicular Lymphoma

Management Challenges in CLL

Updates in Lymphoma From Recent Congresses

Overview. Maximizing the Safety of CAR T-Cell Therapy: Prevention, Early Recognition, and Management.

From Symptom Management to Communication in Advanced GI Cancers

Forming Effective Individualized Treatment Plans for Patients With Low-Risk MDS.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Practical Guidance on Using New Therapies for Relapsed/ Refractory Follicular Lymphoma and Chronic Lymphocytic Leukemia.

Targeting Osteoporosis Therapies to Patients at Highest Risk for Fracture.

Evaluating Next-Generation BTK Inhibitors

Navigating New Oral Treatment Algorithms in CLL

Managing Adverse Events With New Oral Therapies in CLL

Implementing BCR Signaling Inhibitor Therapy in Relapsed CLL

Optimizing Outcomes and Managing Adverse Events in CLL

Minimal Residual Disease in CLL

Poor Response to Initial Therapy for Migraine

Mutational Testing to Select Novel Targeted Therapies in AML

An Interprofessional Perspective on the Safe and Appropriate Use of Opioid Analgesics.

Personalized Therapy in Relapsed or Refractory CLL

Non-Chemotherapy Combinations in CLL

Managing Patients with Relapsed CLL who Discontinue BCR Signaling Inhibitors.

Individualizing Therapy for Patients With CLL in the Community Practice Setting: Focus on Age and Comorbidities.

The Adherence Challenge in Schizophrenia Roles of Current and Emerging Therapies.

VOD/SOS: Aligned Education for Patients and the Interprofessional Team

A Nursing Perspective on Improving Outcomes for Patients With Hemophilia.

Assessing New Paradigms in CLL: MRD Negativity

FDA-Approved PI3K Inhibitors for CLL and FL

Communicating With Your Patients About Major Depressive Disorder

Managing CLL With BTK Inhibitors

First-Line FCR: Effect of del(17p) on PFS and OS

Improving Adherence to Antiplatelet Therapy After an ACS Event

Assessing the Burden of Hyperkalemia

Oral Treatment Strategies in CLL

Tailoring Therapy in the Newly Diagnosed Patient With CLL

Assessing the Burden of Hyperkalemia

Clinical Considerations in Evidence-based Management of GIST

How to Select Therapy in Relapsed/Refractory CLL

The Changing Goals of CML Therapy

An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia,

The Nurse View: Spotlight on EGFR-Mutated NSCLC

Targeting Apoptosis in AML

Clinical Pearls in the Management of Patients With Advanced Non-Small Cell Lung Cancer.

Mitigating Side Effects and Optimizing Compliance With Oral Therapies in CLL.

Changing Paradigms in Relapsed/Refractory Indolent NHL

Treatment Initiation and Selection in Newly Diagnosed CLL

Shared Decision Making in MS

Interprofessional Approach to Managing Adverse Events of PI3K Inhibitors.

Utilizing MRD Assessment in Community Practice

Presentation transcript:

Interprofessional Approaches: Managing AEs of Novel Therapies for NHL/CLL

Treatment of NHL/CLL

Ibrutinib

Ibrutinib Common AEs

Ibrutinib Common AEs (cont)

Ibrutinib Common AEs (cont)

Ibrutinib: Life-Long Therapy Facilitating Long-Term Adherence

Idelalisib

Idelalisib (cont)

Idelalisib Managing Diarrhea

Idelalisib (cont)

Venetoclax

Cairo-Bishop Definition of Laboratory TLS for Adults

TLS Risk Assessment for Lymphomas

Managing Venetoclax-Related TLS Use in High-Risk Patients

Venetoclax Mitigating Additional Risks

Obinutuzumab

Obinutuzumab Additional Risks

Working With Patients Over the Long Term It Takes an Army

Shared Decision-Making for Mitigating and Managing AEs

Abbreviations

Abbreviations (cont)